Zacks Research Upgrades NextCure (NASDAQ:NXTC) to “Hold”

NextCure (NASDAQ:NXTC) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a report on Monday, April 27th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $23.00.

NextCure Stock Down 6.7%

Shares of NASDAQ NXTC opened at $2.08 on Thursday. The business has a fifty day simple moving average of $8.56 and a two-hundred day simple moving average of $11.00. The firm has a market cap of $7.51 million, a PE ratio of -0.12 and a beta of 1.30. NextCure has a twelve month low of $2.00 and a twelve month high of $15.74.

NextCure (NASDAQ:NXTC) last issued its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. On average, research analysts expect that NextCure will post -7.9 earnings per share for the current year.

Institutional Investors Weigh In On NextCure

Large investors have recently modified their holdings of the business. Marshall Wace LLP purchased a new stake in shares of NextCure during the fourth quarter worth about $160,000. Millennium Management LLC purchased a new stake in NextCure during the 4th quarter valued at about $185,000. Geode Capital Management LLC grew its stake in NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares during the last quarter. Renaissance Technologies LLC grew its stake in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in NextCure during the 4th quarter valued at about $988,000. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.